🇺🇸 FDA
Pipeline program

Tafolecimab

2021-CXGC03-002

Unknown small_molecule active

Quick answer

Tafolecimab for Acute Coronary Syndrome is a Unknown program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Acute Coronary Syndrome
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials